Document is current
Any future updates will be listed below
-
Authors
Tee, Mian Zi
Er, Yi Xian
Easton, Alice V.
Yap, Nan Jiun
Lee, Ii Li
Devlin, Joseph
Chen, Ze
Ng, Kee Seong
Subramanian, Poorani
Angelova, Angelina
Oyesola, Oyebola
Sargsian, Shushan
Ngui, Romano
Beiting, Daniel P.
Boey, Christopher Chiong Meng
Chua, Kek Heng
Cadwell, Ken
Lim, Yvonne Ai Lian
Loke, P’ng
Lee, Soo Ching
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (5R01AI130945, 5R01AI130945)
Fundamental Research Grant Scheme (FP004-2017A)
University of Malaya Special Research Fund Assistance (BKS005-2017)
National Institutes of Health
- License Information
-
More Information
Article History
Received: 21 January 2022
Accepted: 4 October 2022
First Online: 7 December 2022
Declarations
:
: This study was approved by the Medical Ethics Committee of Universiti Malaya Medical Centre (Reference No.: 2017925-5593), National Medical Research Register (NMRR), Ministry of Health, Malaysia (Reference No.: NMRR-17-3055-37252), New York University Institutional Review Board (Reference No: i17-01068), the Department of Orang Asli Development (JAKOA) (Reference No.: JAKOA/pp.30.052Jld13 [] and JAKOA/pp.30.052Jld14 []), and the chieftains of respective villages (Tok Batin) before enrolling the indigenous community in this study. An oral briefing using Malay language (the national language for Malaysia) on the purpose and the procedure of this study were explained to all the participants by the investigator. Written consent was attained from all adult participants aged 18 and older. For children under age 18 years, written parental consent was obtained from their respective parents or guardian, and an assent form was obtained from children aged 7 to 17 years. Study exclusion criteria consisted of pregnant women, breastfeeding mothers, and the presence or perceived presence of any clinically significant disease.
: Not applicable.
: Ken Cadwell has received research support from Pfizer, Takeda, Pacific Biosciences, Genentech, and Abbvie. Ken Cadwell was consulted for or has received honoraria from Puretech Health, Genentech, and Abbvie. Ken Cadwell holds US patent 10,722,600 and provisional patents 62/935,035 and 63/157,225. The other authors declare that they have no competing interests.
